BayPine to Acquire CenExel Clinical Research
April 14, 2025
BayPine entered into a definitive agreement to acquire CenExel Clinical Research, a nationwide clinical trial site network focused on complex therapeutic areas. After closing, BayPine will be the majority investor in CenExel alongside Webster Equity Partners, which will retain a minority stake, with management continuing to hold equity.
- Buyers
- BayPine, Webster Equity Partners
- Targets
- CenExel Clinical Research, Inc.
- Industry
- Healthcare Services
- Location
- United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.